RATIONALE-305

NCT03777657 📎

Regimen

Experimental
tislelizumab + chemotherapy
Control
placebo + chemotherapy

Population

HER2-negative advanced gastric/GEJ adenocarcinoma as first-line therapy

Key finding

PD-L1 TAP>=5%: mOS 17.2 vs 12.6 mo (HR 0.74); ITT mOS 15.0 vs 12.9 mo (HR 0.80, p=0.001); safety similar

Source: PMID 38806195

Timeline

    Guideline citations

    • NCCN GASTRIC (p.30)
    • CSCO GASTRIC 2025 (p.98)⚠️ OCR source